Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

24.29 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7
Open 24.29
Bid (Size) 23.00 (6,000)
Ask (Size) 25.50 (200)
Prev. Close 24.29
Today's Range 24.29 - 24.29
52wk Range 8.580 - 25.59
Shares Outstanding 69,484,053
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template ↗
Via Chartmill

Performance

YTD
+14.0%
+14.0%
1 Month
+1.7%
+1.7%
3 Month
+20.1%
+20.1%
6 Month
+48.1%
+48.1%
1 Year
+120.6%
+120.6%

More News

Read More
News headline image
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗
Via The Motley Fool
Topics Regulatory Compliance
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q4 2025 Results with Revenue Beat and Wider-Than-Expected Loss ↗
Via Chartmill
News headline image
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗
Via The Motley Fool
News headline image
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax (SNDX) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Participation in March Investor Conferences
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Syndax Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Syndax Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Syndax Pharmaceuticals, Inc. - Common Stock trade on?
Syndax Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock is SNDX on the Nasdaq Stock Market
What is the current price of Syndax Pharmaceuticals, Inc. - Common Stock?
The current price of Syndax Pharmaceuticals, Inc. - Common Stock is 24.29
When was Syndax Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Syndax Pharmaceuticals, Inc. - Common Stock was at 04/06/26 04:00 PM ET
What is the market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock is 1.69B
How many shares of Syndax Pharmaceuticals, Inc. - Common Stock are outstanding?
Syndax Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.